Indakaterol

Indakaterol
Klinički podaci
Prodajno ime	Arcapta, Hirobriz, Onbrez, Onbrize
Drugs.com	Monografija
Način primene	Respiratorno (inhalacija)
Farmakokinetički podaci
Poluvreme eliminacije	45,5 - 126 h
Izlučivanje	Fekalno (54%)
Identifikatori
CAS broj	312753-06-3
ATC kod	R03AC18 (WHO)
PubChem	CID 6433117
DrugBank	DB05039
ChemSpider	5293751
ChEBI	CHEBI:68575
ChEMBL	CHEMBL1095777
Hemijski podaci
Formula	C24H28N2O3
Molarna masa	392,491
	SMILES CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1; ;
	InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 ; Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N ;
Fizički podaci
Tačka topljenja	195—202 °C (383—396 °F)

Indakaterol je organsko jedinjenje, koje sadrži 24 atoma ugljenika i ima molekulsku masu od 392,491 Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine[уреди | уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	4
Broj donora vodonika	4
Broj rotacionih veza	6
Particioni koeficijent^[7] (ALogP)	3,9
Rastvorljivost^[8] (logS, log(mol/L))	-6,5
Polarna površina^[9] (PSA, Å²)	81,6

Reference[уреди | уреди извор]

^ Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007 Mar;29(3):575-81. Epub 2006 Nov 29. PMID 17135231
^ Australian Public Assessment Report:http://www.tga.gov.au/pdf/auspar/auspar-onbrez.pdf Архивирано на сајту Wayback Machine (12. фебруар 2014)
^ Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012 Sep;40(9):1712-22. doi: 10.1124/dmd.112.046151. Epub 2012 May 30. PMID 22648561
^ Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. PMID 23641160
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди